TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

The Guardant360 assay kits

Pathology dissection instruments and supplies
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The Royal Marsden NHS Foundation Trust: "The Guardant360 assay kits". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityThe Royal Marsden NHS Foundation TrustScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: The Royal Marsden NHS Foundation Trust
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for The Royal Marsden NHS Foundation Trust. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
2Bids / Report
80% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 16 active published awards; 5 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityThe Royal Marsden NHS Foundation Trust
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published8 Jun 2022, 14:30 BST
Last source update8 Jun 2022, 14:30 BST
Recurring procurementNot published
ClassificationPathology dissection instruments and supplies
Delivery area
UK
OCIDocds-h6vhtk-03444c
What is being bought
The Guardant360 assay kits are required to deliver the Trust's partnership agreement with Guardant Health. This is the only kit that can be used to deliver this and is included in the contract requirements with Guardant.
What changed
From the official release history
  1. Status changed to complete
    8 Jun 2022, 14:30 BST
  2. Official notice release published
    8 Jun 2022, 14:30 BST
  3. Buyer information updated
    8 Jun 2022, 14:30 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    The G360 assay designed by Guardant Health is run using Guardant's proprietary sequencing reagents and bioinformatics pipeline and as such an alternative sequencing assay cannot be used. This is direct award to Guardant Health due to designed kits which are needed to run the Guardant assay.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    8 Jun 2022, 14:30 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 15 Oct 2021, 00:00 BST · £1,638,336
Commercial outcome and competition
Awards
Guardant Health
Not published · Not published · active
Contracts
Contract
£1,638,336 · signed 15 Oct 2021, 00:00 BST · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

The Royal Marsden NHS Foundation Trust

Contracting authority GB-FTS-2920
View buyer profile
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleThere is only one supplier i.e. Guardant, we have to use their kit to run the Guardant assay, there is no alternative. We have formed a partnership with Guardant to provide this service. Guardant360 CDx utilizes circulating tumour DNA (ctDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). Guardant360® CDx is a qualitative custom designed next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes.